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fore, this case illustrates the need to assess toxoplas-
mosis serology pretransplant and to use effective pro-
phylaxis. The analogous situation in HIV patients
suggests that absolute levels of lymphocyte subsets
may be of value in determining the duration of pro-
phylaxis in Allo-SCT patients.
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Treatment of Severe
Hemorrhagic Cystitis after
Allogeneic Stem Cell
Transplantation with
Palifermin, a Recombinant
Human Keratinocyte
Growth Factor
Hemorrhagic cystitis (HC) is common after high-
dose therapy and allogeneic stem cell transplantation
[1,2]. The severity of this complication ranges from
asymptomatic macrohematuria to excessively painful
and sometimes life-threatening bleeding. Direct tox-
icity from cytotoxic agents like cyclophosphamide and
reactivation of a latent infection with polioma or ad-
enovirus during episodes of profound immunosup-
pression are supposed to be involved in its pathogen-
esis [3,4]. Once diagnosis has been made, the
treatment of hemorrhagic cystitis is polypragmatic
and often ineffective.
Palifermin is a recombinant human keratinocyte
growth factor (KGF), a member of the ﬁbroblast
growth factor (FGF) family, which binds speciﬁcally
to the human KGF receptor and induces proliferation
and differentiation of epithelial cells, including gas-
trointestinal epithelial cells, hepatocytes, type II pneu-
mocytes, and transitional urothelial cells [5]. It has
been approved for prophylaxis of oral and gastrointes-
tinal mucositis in the context of high-dose therapy and
autologous as well as allogeneic stem cell transplanta-
tion [6]. We here describe the ﬁrst successful treat-
ment of severere hemorrhagic cystitis with Palifermin.
A-24-year old man suffered from refractory T-
acute lymphoblastic leukemia (ALL). He achieved a
ﬁrst remission after experimental treatment with
Ara-G, and received an allogeneic stem cell transplant
from an unrelated donor following conditioning with
Fludarabine, high-dose Cytarabine, Amsacrine, and
total body irradiation (TBI) (12 Gy). The early clinical
course was uneventful and the patient had hematopoi-
etic reconstitution of white blood cells (WBC) on day
14. The patient’s blood was weekly screened for
cytomegalovirus (CMV), Ebstein-Barr virus (EBV),
adenovirus, herpes simplex virus type-1 and -2, human
herpes virus 6, and BK-virus (BKV) infections with all
negative results. Twenty-ﬁve days after transplanta-
tion, he developed acute graft-versus-host disease
(aGVHD) III grade of the skin and gastrointestional
(GI) tract, which responded to combined therapy with
steroids and basiliximab. Steroids could be discontin-
ued on day 33 with resolving of GVHD of the GI
Figure 2. Lymphocyte subsets over time.
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tract. The GVHD of the skin did not resolve com-
pletely, but became chronic and needed an ongoing
posttransplant immunosuppression with Cyclosporin
A (CSA), maintaining serum levels between 150 and
50 mg/dL. Because of this prolonged immunosuppres-
sive therapy, immune reconstitution is still incomplete
within all T-lymphocyte subsets. On day 33 the pa-
tient developed painful hematuria. At that time, urine
was positive for BKV (1.5  108 copies/mL). The
treatment was initiated promptly and consisted of per-
manent bladder irrigation (200 L/day), Cidofovir (375
mg) (on days 33, 40, 57, 75, and 85) and
intravenous immunoglobulins (30 g per dose). Cysto-
scopic evaluation showed diffuse multifocal inﬂamma-
tion and bleeding. Clinical and laboratory ﬁndings
were consistent with the diagnosis of severe posttrans-
plant hemorrhagic cystitis.
Despite treatment, the clinical condition wors-
ened and the patient needed up to 8 units of packed
red blood cells (PRBCs) per day to maintain a hemo-
globin level of5 g/dL. At this time point we decided
to introduce a combined treatment with oral estrogens
(5 mg/day) and Palifermin (60 g/kg, 3 days a week).
Estrogens had to be stopped after 7 days because of
severe liver toxicity, but KGF was well tolerated. A
few days after starting Palifermin, bleeding severity
improved and repeated cystoscopy now showed more
localized leasons that were tried to coagulate. In ad-
dition, Uropol S, a chondroitin sulphate, was given
intravesically on several occasions. However, bleeding
intermittently continued and the patient received 12
more doses of Palifermin. Finally, bleeding stopped
and bladder irrigation could be discontinued after 96
days. A few days later hematuria reappeared, but re-
solved after additional treatment with Palifermin (see
Figure 1). At present, the patient is alive in remission
without HC 463 days after transplantation.
Hemorrhagic cystitis is a severe and potentially
life-threatening complication after allogeneic stem
cell transplantation [1]. Pathogenesis is not fully un-
derstood, but there is some evidence that three ele-
ments are essential for the development of HC: dam-
age to the bladder epithelium, BK-virus replication,
and alloimmunity [7,8]. Consequently, treatment has
tried to aim at virus replication, which has been suc-
cessful in some cases. However, a large proportion of
patients do not respond to antiviral therapy, and the
remaining therapeutic options are rather empiric and
include systemic estrogens, instillation of formalin, or
even cystektomy [9]. Once established, there is con-
stant destruction of urothelium either because of viral
replication or as a result of alloimmune cytolytic
mechanisms. KGF may be able to modify this process
and improve wound healing as has been shown in
other experimental models of bladder injury.
Palifermin is a human KGF that acts on several
epithelial tissues. It has been approved to reduce mu-
cositis after high-dose therapy and stem cell transplan-
tation. Several authors have demonstrated a prolifer-
ative and antiapoptotic effect on human urothelium.
Using an animal model, Ulich et al. [10] could dem-
onstrate that HC induced by cyclophosphamide could
almost completely be prevented by the application of
KGF before chemotherapy. It is tempting to suggest,
that a combination of antiviral therapy and protection
of the bladder epithelium by Palifermin may be more
successful than conventional therapy for HC. We
have used KGF to treat severe HC late in the course
of the disease in a patient where antiviral and support-
ive therapy alone was not effective. KGF may be even
Figure 1. Clinical course of the patient after transplantation.
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more effective when used earlier, that is, at ﬁrst oc-
currence of hematuria or even prophylactically in pa-
tients with extraordinary high BKV titers.
Although unlikely, we cannot rule out that the
short course of estrogens, coagulation, or instillation
of Uropol S also contributed to the ﬁnal resolution of
HC in our patient. However, timing of these inter-
ventions and the known cytoprotective and prolifera-
tive effects of KGF suggests, that Palifermin may be
an important component in a combined modality ap-
proach combining antiviral and growth factor therapy
to treat HC after allogeneic stem cell transplantation.
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